All News

The FDA has approved durvalumab combined with carboplatin and paclitaxel, followed by single-agent durvalumab.

At a session of the European Hematology Association 2024 Congress, presenters shared updates from trials of treatment strategies for newly diagnosed multiple myeloma (MM).

Two posters presented at the 2024 American Society of Clinical Oncology annual meeting revealed real-world data on the outcomes and management strategies associated with melanoma during pregnancy.

Researchers have found that specific genetic markers may increase the risk of cardiovascular adverse effects in patients using Bruton’s tyrosine kinase (BTK) inhibitors.

Investigators from Germany conducted a systematic review of different MRI features in soft tissue sarcoma (STS) that are used to infer tumor histological grade.

The Center on Health Equity & Access shares the latest news, research, and expert insights on developments related to health disparities, gaps in care, and initiatives to address them.

At a friendly debate held at the European Hematology Association 2024 Congress, hemophilia experts argued for and against wider access to gene therapy for patients living with the condition.

This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.

A recent study found that neighborhood deprivation is associated with higher breast cancer death rates for non-Hispanic White women, but not Black women. This suggests factors beyond socioeconomic status contribute to the racial disparity.

Adults aged 70 and older were significantly more likely to develop congestive heart failure if they also experienced olfactory impairment.

Michael Thorpy, MD, professor of neurology, Albert Einstein College of Medicine, explored the mechanism of action in orexin agonists, which has been indicated for idiopathic hypersomnia.

Neurotrophic tyrosine receptor kinase (NTRK)–positive locally advanced or metastatic solid tumors can now be treated with the first FDA-approved treatment option.

Abstracts presented at the 2024 European Hematology Association Congress deliver results on regimens involving venetoclax for chronic lymphocytic leukemia (CLL).

Results presented at the 2024 European Hematology Association Congress suggest that chimeric antigen receptor (CAR) T-cell therapy can be feasibly and safely delivered in the outpatient setting as treatment for lymphoma.

The arrests of the founders of Done Global, a telehealth company that provides attention-deficit/hyperactivity disorder (ADHD) medication to adults, for allegedly providing prescriptions to unqualified patients and defrauding the government have raised concerns about future access to these medications; US health care spending rose to $4.8 trillion in 2023; bipartisan legislation has been introduced to reform prior authorization with Medicare Advantage.

At a YoungEHA session at the 2024 European Hematology Association (EHA) Congress, speakers discussed the prevalence of waste in laboratories, research, and clinical practice, as well as ways attendees can effect change for a more sustainable future.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

At the 2024 American Society of Clinical Oncology annual meeting, an abstract presenting real-world data stressed the need for further research regarding the association between immunosuppressant medication and the development of skin cancer.

Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for these young patients, particularly those who are Black.

The most common treatment-related adverse events were injection site reactions, the study found.

Nivolumab/cabozantinib combination therapy showed consistent benefits across various subgroups in patients with advanced renal cell carcinoma (RCC).

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive disease.

Different Janus kinase (JAK) inhibitors underwent an evaluation for severe alopecia areata (AA) and found deuruxolitinib higher doses (12 mg) and baricitinib (4 mg) showed promise in hair regrowth improvement, but further research must be done to confirm these results while more long-term effects are explored.

Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults.

Researchers have identified a causal link between gut microbiota and myelodysplastic syndrome (MDS) risk, mediated by certain key immune cell phenotypes.

FDA and the Department of Justice were criticized during a Senate hearing on the youth vaping crisis; a new COVID-19 vaccine promises easier storage and superior protection; the Supreme Court ruled to allow mifepristone to be mailed to patients without an in-person doctor’s visit.

One patient died during this study, which used PET/CT, flow cytometry, and next-generation sequencing to define measurable residual disease negativity.

In a recent update, the National Comprehensive Cancer Network (NCCN) recommended capivasertib combined with fulvestrant for hormone receptor–positive and HER2-negative locally advanced or metastatic breast cancer, targeting patients with specific genetic mutations.